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Background and aim
We have previously reported a more advanced radiologi-
cal presentation in HIV+/HCV+ than HIV-/HCV+
patients (pts). The aim of our study was to define prog-
nostic factors of death in HIV+/HCV+ pts with HCC.
Methods
Cases of HCC in HIV+/HCV+ pts were obtained from
the 3 ANRS Prethevic, HepaVih and CirVir cohorts.
Imaging was reviewed according to EASL criteria.
Results
Fifty HIV+/HCV+ coinfected pts (n=44 men (88%), med-
ian age 50 years [40-74], median CD4 cell count 334/mm3
[58-1621], n=28 Child A cirrhosis (60%)) developed HCC.
Thirty-one (63%) pts presented cirrhosis decompensation
before HCC diagnosis. At HCC diagnosis, median serum
aFP was 20.4 [1.9-198,900] ng/ml, 38 (76%) pts had a nod-
ular tumor (median main diameter 23.5 [11-70] cm) and
12 (24%) pts an infiltrating form (62.5 [10-130] cm),
p=0.007. Tumor portal thrombosis was diagnosed in 14
(28%) pts. A curative or a palliative procedure was further
performed in 22 (44%) pts and 20 (40%) pts, respectively.
The 2-years and 4-years overall survival rates were 51%
and 28%, respectively. Age (p=0.0005), infiltrating or nod-
ular tumor (p= 0.0009) and tumor portal thrombosis
(p=0.004) were associated to survival. In a Cox model, two
prognostic factors of deaths were found: prior episode
of cirrhosis decompensation (aRR 11.43 [3.01-43.34],
p=0.0003) and tumor portal thrombosis (aRR 4.66
[1.19-18.27], p=0.03), adjusted on age, CD4 cell count and
the therapeutic strategy for HCC.
Conclusions
Cirrhosis decompensation and tumor portal thrombosis
significantly impact the survival of HIV+/HCV+ pts with
HCC. Our results suggest new rules of screening HCC in
HIV+/HCV+ pts with advanced liver disorders.
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